Abstract
We have screened for germline TP53 mutations in Finnish BRCA1 and BRCA2 mutation-negative families. This study represents the largest survey of the entire protein-encoding portion of TP53, and indicates that mutations are only found at conserved domains in breast cancer families also meeting the criteria for Li-Fraumeni/Li-Fraumeni-like syndrome, explaining only a very small additional fraction of the hereditary breast cancer cases. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DCR, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE and Haber DA (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286: 2528–2531
Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Morris Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans GR, Thompson E, Mann JR, Martin J, Mitchell ELD and Santibanez-Koref MF (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54: 1298–1304
Boerresen A-L, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, Ottestad L, Smith-Soerensen B, Hovig E, Malkin D and Friend SH (1992) Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52: 3234–3236
Cho Y, Gorina S, Jeffrey PD and Pavletich NP (1994) Crystal structure of a p53 tumour suppressor-DNA complex: understanding tumorgenic mutations. Science 267: 1353–1356
Claus EB, Schildkraut JM, Thompson WD and Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77: 2318–2324
Cornelis RS, van Vliet M, van de Vijver MJ, Vasen HFA, Voute PA, Top B, Meera Khan P, Devilee P and Cornelisse CJ (1997) Three germline mutations in the TP53 gene. Hum Mutat 9: 157–163
Diller L, Sexsmith E, Gottlieb A, Li FP and Malkin D (1995) Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest 95: 1606–1611
Easton DF (1999) How many more breast cancer predisposition genes are there?. Br Cancer Res 1: 14–17
Eng C, Schneider K, Fraumeni JF and Li FP (1997) Third international workshop on collaborative interdisciplinary studies of p53 and other predisposing genes in Li-Fraumeni syndrome. Cancer Epidemiol Biomark Prev 6: 379–383
Ganguly T, Dhulipala R, Godmilow L and Ganguly A (1998) High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families. Hum Genet 102: 549–556
Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) p53 mutations in human cancer. Science 253: 49–53
Huusko P, Pääkkönen K, Launonen V, Pöyhönen M, Blanco G, Kauppila A, Puistola U, Kiviniemi H, Kujala M, Leisti J and Winqvist R (1998) Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet 62: 1544–1548
Huusko P, Castrén K, Launonen V, Soini Y, Pääkkönen K, Leisti J, Vähäkangas K and Winqvist R (1999) Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2. Cancer Genet Cytogenet 112: 9–14
Kainu T, Juo S-HH, Desper R, Schäffer AA, Gillanders E, Rozenblum E, Freas-Lutz D, Weaver D, Stephan D, Bailey-Wilson J, Kallioniemi O-P, Tirkkonen M, Syrjäkoski K, Kuukasjärvi T, Koivisto P, Karhu R, Holli K, Arason A, Johannesdottir G, Bergthorsson JT, Johannsdottir H, Egilsson V, Björk Barkardottir R, Johannsson O, Haraldsson K, Sandberg T, Holmberg E, Grönberg H, Olsson H, Borg Å, Vehmanen P, Eerola H, Heikkilä P, Pyrhönen S and Nevanlinna H (2000) Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci USA 97: 9603–9608
Lasky T and Silbergeld E (1996) p53 mutations associated with breast, colorectal, liver,lung and ovarian cancers. Environ Health Perspectives 104: 1324–1331
Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323–331
Lidereau R and Soussi T (1992) Absence of p53 germ-line mutations in bilateral breast cancer patients. Hum Genet 89: 250–252
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PD, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow BK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A and Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71
Nyström-Lahti M, Kristo P, Nicolaides NC, Chang SY, Aaltonen LA, Moisio AL, Järvinen HJ, Mecklin JP, Kinzler KW, Vogelstein B, de la Chapelle A and Peltomäki P (1995) Founding mutations and Alu-mediated recombination in hereditary colon cancer. Nat Med 1: 1203–1206
Patel UA, Perry M and Crane-Robinson C (1995) Screening for germline mutations of the p53 gene in familial breast cancer patients. Eur J Clin Invest 25: 132–137
Prosser J, Elder PA, Condie A, MacFadyen I, Steel CM and Evans HJ (1991) Mutations in p53 do not account for heritable breast cancer: a studey in five affected families. Br J Cancer 63: 181–184
Sarantaus L, Huusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K, Gillanders E, Syrjäkoski K, Kainu T, Vahteristo P, Krahe R, Pääkkönen K, Hartikainen J, Blomqvist C, Löppönen T, Holli K, Ryynänen M, Bützow R, Borg Å, Wasteson Arver B, Holmberg E, Mannermaa A, Kere J, Kallioniemi O-P, Winqvist R and Nevanlinna H (2000) Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet,
Shibata A, Tsai YC, Press MF, Henderson BE, Jones PA and Ross RK (1996) Clonal analysis of bilateral breast cancer. Clin Cancer Res 2: 743–748
Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Vogelstain B and Davidson N (1992) Inherited p53 gene mutations in breast cancer. Cancer Res, 2984–2986
Syvänen A-C (1999) From gels to chips: “Minisequencing” primer extension for analysis of point mutations and single nucleotide polymorphisms. Hum Mutat 13: 1–10
Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, Weichselbaum RR and Yandeli DW (1992) Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 320: 1301–1308
Varley JM, Evans CGR and Birch JM (1997a) Li-Fraumeni syndrome – a molecular and clinical review. Br J Cancer 76: 1–14
Varley JM, McGown G, Thorncroft M, Santibanez-Koref M, Kelsey AM, Tricker KJ, Evans GR and Birch JM (1997b) Germ-Line Mutations of TP53 in Li-Fraumeni Families: An Extended Study of 39 Families. Cancer Res 57: 3245–3252
Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi O-P, Muhonen T, Luce M, Frank TS and Nevanlinna H (1997a) Low porpotion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 6: 2309–2315
Vehmanen P, Friedman LS, Eerola H, Sarantaus L, Pyrhönen S, Ponder ABJ, Muhonen T and Nevanlinna H (1997b) A low porpotion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet 60: 1050–1058
Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA and Malkin D (1994) High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86: 1707–1710
Warren W, Eeles RA, Ponder BAJ, Easton DF, Averill D, Ponder MA, Anderson K, Evans AM, DeMars R, Love R, Dundas S, Stratton MR, Trowbridge P, Cooper CS and Peto J (1992) No evidence for germline mutations in exons 5–9 of the p53 gene in 25 breast cancer families. Oncogene 7: 1043–1046
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkardottir RB, Easton DF, Bentley DR, Futreal PA, Ashworth A and Stratton MR (1995) Indentification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792
Zelada-Hedman M, Boerresen-Dale A-L, Claro A, Chen J, Skoog L and Lindblom A (1997) Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families. Br J Cancer 75: 1201–1204
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Rapakko, K., Allinen, M., Syrjäkoski, K. et al. Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. Br J Cancer 84, 116–119 (2001). https://doi.org/10.1054/bjoc.2000.1530
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1530
Keywords
This article is cited by
-
Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion
BMC Cancer (2012)
-
A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas
Modern Pathology (2011)
-
Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population
Breast Cancer Research and Treatment (2010)
-
Mutation analysis of the AATF gene in breast cancer families
BMC Cancer (2009)
-
Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function
Oncogene (2009)